Clinical trial

177Lu-PSMA-EB-01 in Patients With Metastatic Castration-resistant Prostate Cancer

NCT05613738

Drugs and interventions used in this trial

3 registered

These interventions are listed by ClinicalTrials.gov. An RxNorm link indicates a mapped medicine record; the registry name alone is not proof of a specific branded formulation.

Search this trial's interventions

DRUG · Unmapped registry intervention 1.11 GBq (30 mCi) of 177Lu-PSMA-EB-01 Find medicine records · Find other trials using this name

DRUG · Unmapped registry intervention 1.85 GBq (50 mCi) of 177Lu-PSMA-EB-01 Find medicine records · Find other trials using this name

DRUG · Unmapped registry intervention 2.59 GBq (70 mCi) of 177Lu-PSMA-EB-01 Find medicine records · Find other trials using this name

Study at a glance

Registry-backed

177Lu-PSMA-EB-01 in Patients With Metastatic Castration-resistant Prostate Cancer

Design: INTERVENTIONAL · Status: UNKNOWN · Phase: NA

Read study objectives, eligibility and outcome measures at ClinicalTrials.gov

StatusUNKNOWN

Study typeINTERVENTIONAL

Start date2022-11-23

PhaseNA

Conditions

Metastatic Castration-resistant Prostate Cancerunresolved

Interventions

1.11 GBq (30 mCi) of 177Lu-PSMA-EB-01DRUG

1.85 GBq (50 mCi) of 177Lu-PSMA-EB-01DRUG

2.59 GBq (70 mCi) of 177Lu-PSMA-EB-01DRUG

Sponsors & collaborators

Peking Union Medical College Hospitallead sponsor

Mapped research locations

BeijingBeijing Municipality, China1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT05613738 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.